

**MOUWASAT MEDICAL SERVICES COMPANY AND ITS
SUBSIDIARIES**
(A Saudi Joint Stock Company)
INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
FOR THE YEAR ENDED 31 DECEMBER 2015



EY

Building a better
working world



Ernst & Young & Co. (Public Accountants)
4th Floor – Juffali Building
PO Box 3795
Al Khobar 31952
Saudi Arabia
Registration Number: 45

Tel: +966 13 849 9500
Fax: +966 13 882 7224

www.ey.com

**LIMITED REVIEW REPORT TO THE SHAREHOLDERS OF
MOUWASAT MEDICAL SERVICES COMPANY
(A SAUDI JOINT STOCK COMPANY)**


Scope of limited review:

We have reviewed the accompanying interim consolidated balance sheet of Mouwasat Medical Services Company, A Saudi Joint Stock Company ("the Company") and its subsidiaries (collectively referred to as "the Group") as at 31 December 2015, and the related interim consolidated statements of income for the three months period and the year then ended and the interim consolidated statements of cash flows and changes in shareholders' equity for the year then ended. These interim consolidated financial statements have been prepared by the Company's management and submitted to us together with all the information and explanations which we required. We conducted our limited review in accordance with Standard on Review of Interim Financial Reporting issued by the Saudi Organization of Certified Public Accountants ("SOCPA"). A limited review consists principally of applying analytical procedures to financial data and making inquiries of the persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with generally accepted auditing standards, the objective of which is the expression of an opinion regarding the consolidated financial statements taken as a whole. Accordingly, we do not express such an opinion.

Conclusion:

Based on our limited review, we are not aware of any material modifications that should be made to the accompanying interim consolidated financial statements for them to be in conformity with accounting standards generally accepted in the Kingdom of Saudi Arabia.

for Ernst & Young



Abdulaziz Saud Alshubaili
Certified Public Accountant
Registration No.339



11 Rabi' II 1437 H
21 January 2016

Al-Khobar

Mouwasat Medical Services Company and its Subsidiaries
(A Saudi Joint Stock Company)


INTERIM CONSOLIDATED BALANCE SHEET

As at 31 December 2015

	Note	31 December 2015 SR (Unaudited)	31 December 2014 SR (Audited)
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents		81,002,808	181,565,236
Term deposits	4	150,000,000	100,000,000
Accounts receivable and prepayments		277,223,887	219,880,365
Inventories		105,310,790	75,806,237
TOTAL CURRENT ASSETS		613,537,485	577,251,838
NON-CURRENT ASSETS			
Investment in an associate		8,743,603	8,530,030
Advances to contractor		23,308,370	15,222,744
Property and equipment		1,212,212,028	1,082,496,297
Goodwill		16,371,000	16,371,000
Other intangible assets		1,053,382	685,452
TOTAL NON-CURRENT ASSETS		1,261,688,383	1,123,305,523
TOTAL ASSETS		1,875,225,868	1,700,557,361
LIABILITIES AND SHAREHOLDERS' EQUITY			
CURRENT LIABILITIES			
Accounts payable and accruals		149,065,389	141,819,187
Short term loans	5	17,176,164	19,083,688
Current portion of term loans		120,881,091	110,948,758
Zakat provision		22,411,354	19,327,287
TOTAL CURRENT LIABILITIES		309,533,998	291,178,920
NON-CURRENT LIABILITIES			
Term loans		309,055,068	280,971,740
Employees' terminal benefits		50,849,918	40,837,948
TOTAL NON-CURRENT LIABILITIES		359,904,986	321,809,688
TOTAL LIABILITIES		669,438,984	612,988,608
SHAREHOLDERS' EQUITY			
Equity attributable to the shareholders of the Company			
Share capital	6	500,000,000	500,000,000
Statutory reserve		144,444,240	123,564,050
Retained earnings		491,602,507	403,680,802
		1,136,046,747	1,027,244,852
NON-CONTROLLING INTERESTS			
		69,740,137	60,323,901
TOTAL SHAREHOLDERS' EQUITY		1,205,786,884	1,087,568,753
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		1,875,225,868	1,700,557,361

The attached notes 1 to 10 form part of these interim consolidated financial statements.


Managing Director
 Mohammed Al Saleem

2

Authorized Board Representative
 Mohammed Al Saleem


Chief Finance Officer
 Mahmoud Soliman

Mouwasat Medical Services Company and its Subsidiaries
(A Saudi Joint Stock Company)


INTERIM CONSOLIDATED STATEMENT OF INCOME

For the three months period and the year ended 31 December 2015

	<i>For the three months period ended 31</i>		<i>For the year ended 31 December</i>	
	<i>December</i>			
Note	2015 SR <i>(Unaudited)</i>	2014 SR <i>(Unaudited)</i>	2015 SR <i>(Unaudited)</i>	2014 SR <i>(Audited)</i>
REVENUE:				
Operating revenue	229,498,346	198,699,791	864,820,169	767,465,214
Sales	46,356,293	48,477,523	189,963,922	185,231,162
	275,854,639	247,177,314	1,054,784,091	952,696,376
DIRECT COSTS:				
Cost of operations	(114,570,527)	(96,401,202)	(416,928,090)	(356,020,940)
Cost of sales	(31,639,716)	(33,289,546)	(136,335,221)	(130,590,987)
	(146,210,243)	(129,690,748)	(553,263,311)	(486,611,927)
GROSS PROFIT	129,644,396	117,486,566	501,520,780	466,084,449
EXPENSES				
Selling and distribution	(36,759,686)	(32,610,760)	(148,870,563)	(128,196,016)
General and administration	(32,081,908)	(31,819,270)	(117,089,364)	(103,941,645)
Amortization of other intangible assets	(141,049)	(200,473)	(657,655)	(780,752)
	(68,982,643)	(64,630,503)	(266,617,582)	(232,918,413)
INCOME FROM MAIN OPERATIONS	60,661,753	52,856,063	234,903,198	233,166,036
Share in results of an associate	750,000	750,000	3,323,055	3,052,172
Other income	2,580,923	5,977,287	8,364,902	32,326,889
Financial charges	(1,632,716)	(533,825)	(7,389,052)	(1,072,719)
INCOME BEFORE ZAKAT AND NON-CONTROLLING INTERESTS	62,359,960	59,049,525	239,202,103	267,472,378
Non-controlling interests	(4,060,817)	(2,525,426)	(14,316,236)	(10,556,267)
INCOME BEFORE ZAKAT	58,299,143	56,524,099	224,885,867	256,916,111
Zakat	(4,499,387)	(5,777,685)	(16,083,972)	(16,797,654)
NET INCOME FOR THE PERIOD/ YEAR	53,799,756	50,746,414	208,801,895	240,118,457
EARNINGS PER SHARE				
Earnings per share from main operations	8 1.21	1.06	4.70	4.66
Earnings per share from net income	8 1.08	1.01	4.18	4.80
Weighted average number of outstanding shares	6 50,000,000	50,000,000	50,000,000	50,000,000

The attached notes 1 to 10 form part of these interim consolidated financial statements.


Managing Director
 Mohammed Al Saleem


Authorized Board Representative
 Mohammed Al Saleem


Chief Finance Officer
 Mahmoud Soliman


Mouwasat Medical Services Company and its Subsidiaries
(A Saudi Joint Stock Company)


INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS


For the year ended 31 December 2015

	<i>For the year ended 31 December</i>	
	2015 SR <i>(Unaudited)</i>	2014 SR <i>(Audited)</i>
OPERATING ACTIVITIES		
Income before zakat and non-controlling interests	239,202,103	267,472,378
Adjustments for:		
Depreciation	51,765,876	41,611,473
Amortization of other intangible assets	657,655	780,752
Share in results of an associate	(3,323,055)	(3,052,172)
Employees' terminal benefits, net	10,011,970	5,071,192
Financial charges	7,389,052	1,072,719
Gain on disposal of property and equipment	(288,985)	(24,464,919)
	<u>305,414,616</u>	<u>288,491,423</u>
Changes in operating assets and liabilities:		
Accounts receivable and prepayments	(57,343,522)	13,542,956
Inventories	(29,504,553)	(8,592,131)
Accounts payable and accruals	7,246,202	6,786,055
Advances to contractor	(23,308,370)	1,560,445
Cash from operations	<u>202,504,373</u>	<u>301,788,748</u>
Financial charges paid	(7,389,052)	(1,072,719)
Zakat paid	(12,999,905)	(13,233,259)
Net cash from operating activities	<u>182,115,416</u>	<u>287,482,770</u>
INVESTING ACTIVITIES		
Term deposits	(50,000,000)	-
Purchase of property and equipment	(166,599,118)	(276,666,978)
Proceeds from disposal of property and equipment	629,240	28,737,847
Additions to other intangible assets	(1,025,585)	(428,135)
Dividend received from an associate	3,109,482	2,585,684
Net cash used in investing activities	<u>(213,885,981)</u>	<u>(245,771,582)</u>
FINANCING ACTIVITIES		
Proceeds from short term loans	-	15,532,197
Repayments of short term loans	(1,907,525)	(13,316,468)
Proceeds from term loans	148,964,425	157,923,296
Repayments of term loans	(110,948,763)	(90,725,965)
Dividends paid	(100,000,000)	(100,000,000)
Movement in non-controlling interests	(4,900,000)	(9,800,000)
Net cash used in financing activities	<u>(68,791,863)</u>	<u>(40,386,940)</u>
(DECREASE)/ INCREASE IN CASH AND CASH EQUIVALENTS	<u>(100,562,428)</u>	<u>1,324,248</u>
Cash and cash equivalents at the beginning of the year	<u>181,565,236</u>	<u>180,240,988</u>
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	<u>81,002,808</u>	<u>181,565,236</u>
NON-CASH TRANSACTION:		
Transfer from advances to contractor to property and equipment	<u>15,222,744</u>	-

The attached notes 1 to 10 form part of these interim consolidated financial statements.


Managing Director
 Mohammed Al Saleem


Authorized Board Representative
 Mohammed Al Saleem


Chief Finance Officer
 Mahmoud Soliman

Mouwasat Medical Services Company and its Subsidiaries
(A Saudi Joint Stock Company)

INTERIM CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY
For the year ended 31 December 2015


EQUITY ATTRIBUTABLE TO THE SHAREHOLDERS OF THE COMPANY

	<i>Share capital</i>	<i>Statutory reserve</i>	<i>Retained earnings</i>	<i>Proposed dividends</i>	<i>Total</i>
	<i>SR</i>	<i>SR</i>	<i>SR</i>	<i>SR</i>	<i>SR</i>
At 1 January 2014 (<i>Audited</i>)	500,000,000	99,552,204	188,974,191	100,000,000	888,526,395
Net income for the year	-	-	240,118,457	-	240,118,457
Transfer to statutory reserve	-	24,011,846	(24,011,846)	-	-
Dividends (note 7)	-	-	-	(100,000,000)	(100,000,000)
Directors' remuneration	-	-	(1,400,000)	-	(1,400,000)
At 31 December 2014 (<i>Audited</i>)	<u>500,000,000</u>	<u>123,564,050</u>	<u>403,680,802</u>	<u>-</u>	<u>1,027,244,852</u>
At 1 January 2015 (<i>Audited</i>)	500,000,000	123,564,050	403,680,802	-	1,027,244,852
Net income for the year	-	-	208,801,895	-	208,801,895
Transfer to statutory reserve	-	20,880,190	(20,880,190)	-	-
Dividends (note 7)	-	-	(100,000,000)	-	(100,000,000)
At 31 December 2015 (<i>Unaudited</i>)	<u>500,000,000</u>	<u>144,444,240</u>	<u>491,602,507</u>	<u>-</u>	<u>1,136,046,747</u>

The attached notes 1 to 10 form part of these interim consolidated financial statements.


Managing Director
Mohammed Al Saleem

5


Authorized Board Representative
Mohammed Al Saleem


Chief Finance Officer
for Mahmoud Soliman

Mouwasat Medical Services Company and its Subsidiaries **(A Saudi Joint Stock Company)**

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

At 31 December 2015

1 ACTIVITIES

Mouwasat Medical Services Company ("the Company") is registered in Saudi Arabia under Commercial Registration number 2050032029 dated 12 Ramadan 1417H (corresponding to 22 January 1997). The Company was converted into a Saudi Joint Stock Company in accordance with Ministerial Resolution No. 1880 dated 4 Dhu-al-Hijja 1426H (corresponding to 4 January 2006).

The Company through its multiple branches is engaged in the acquisition, management, operation and maintenance of hospitals, medical centers, drug stores, pharmacies and wholesale of medical equipment and drugs.

The accompanying interim consolidated financial statements include the activities of the Company and its following subsidiaries (collectively referred to as "the Group"):

<u>Name of the entity</u>	<u>Country of incorporation</u>	<u>Type of the entity</u>	<u>Percentage of ownership</u>
Eastern Medical Services	Saudi Arabia	Limited Liability Company	51%
Specialized Medical Clinic	Saudi Arabia	Limited Liability Company	95%

2 BASIS OF PREPERATION

These interim consolidated financial statements include assets, liabilities and the results of the operations of the Company and its subsidiaries as disclosed in note (1) above. A subsidiary company is that in which the Group has, directly or indirectly, long term investment comprising an interest in the voting capital which it exerts control. A subsidiary company is consolidated from the date on which the Group obtains control until the date that control ceases. The interim consolidated financial statements are prepared on the basis of the individual interim financial statements of the Company and the interim financial statements of its subsidiaries. The interim financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. All intra-Group balances, income and expenses and unrealized gains and losses resulting from intra-Group transactions are eliminated in

Non-controlling interest represents the portion of profit or loss and net assets that are not held by the Group and are presented separately in the interim consolidated statement of income and within shareholders' equity in the interim consolidated balance sheet, separately from shareholders' equity attributable to the Company.

3 SIGNIFICANT ACCOUNTING POLICIES

The accompanying interim consolidated financial statements have been prepared in accordance with the Standard on Review of Interim Financial Reporting issued by the Saudi Organization for Certified Public Accountants ("SOCPA"). The significant accounting policies adopted by the Group in preparing its interim consolidated financial statements, summarized below, are consistent with those used in the preparation of the last audited consolidated financial statements for the year ended 31 December 2014.

Accounting convention

The interim consolidated financial statements are prepared under the historical cost convention.

Mouwasat Medical Services Company and its Subsidiaries

(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS - (continued)

At 31 December 2015

3 SIGNIFICANT ACCOUNTING POLICIES - (continued)

Use of estimates

The preparation of interim consolidated financial statements in conformity with generally accepted accounting principles requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim consolidated financial statements and the reported amounts of revenue and expenses during the reporting period.

Cash and cash equivalents

Cash and cash equivalents consists of bank balances, cash on hand, and Murabaha deposits that are readily convertible into known amounts of cash and have a maturity period of three months or less, when purchased.

Accounts receivable

Accounts receivable are stated at original invoice amount less an allowance for any uncollectible amounts. An estimate for doubtful debts is made when collection of the full amount is no longer probable. Bad debts are written off as incurred.

Inventories

Inventories are stated at the lower of cost and market value. Costs are those expenses incurred in bringing each product to its present location and condition and calculated on purchase cost on a weighted average basis.

Investment in an associate

Investment in associate is accounted for using equity method of accounting.

Property and equipment/depreciation

Property and equipment are initially recorded at cost and are stated at cost less accumulated depreciation and any impairment in value. Freehold land and capital work in progress are not depreciated. The cost of other property and equipment is depreciated on a straight line basis over the estimated useful lives of the assets.

Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life of the improvement or the term of the lease.

Expenditure for repair and maintenance are charged to income as incurred. Improvements that increase the value or the materially extend the useful life of the related assets are capitalised.

Other intangible assets

These represent the license of certain hospitals and dispensaries. Costs which have a long term future benefits are treated as other intangible assets and are amortised over the estimated period of benefit.

Goodwill

Goodwill is measured at cost being the excess of the cost of the business combination over the Group's interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the acquired entity. Following initial recognition, the goodwill is measured at cost less any accumulated impairment losses.

Impairment is determined for goodwill by assessing the recoverable amount of the cash-generating unit (or group of cash-generating units), to which the goodwill relates. Where the recoverable amount of the cash-generating unit (or group of cash-generating units) is less than the carrying amount of the cash-generating unit (or group of cash-generating units) to which goodwill has been allocated, an impairment loss is recognized. Impairment losses relating to goodwill cannot be reversed in future periods.

Mouwasat Medical Services Company and its Subsidiaries

(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS - (continued)

At 31 December 2015

3 SIGNIFICANT ACCOUNTING POLICIES - (continued)

Goodwill - (continued)

Goodwill is reviewed for impairment, annually or more frequently if events or changes in circumstances indicate that the carrying value may be impaired. The Group performs its annual impairment test of goodwill at each reporting date. When subsidiaries are sold, the difference between the selling price and the net assets plus cumulative translation differences and goodwill is recognized in the interim consolidated statement of income.

Impairment of non-current assets

The carrying values of non-current assets are reviewed for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. If any such indication exists and where the carrying values exceed the estimated recoverable amount, the non-current assets are written down to their recoverable amount, being the higher of their fair value less costs to sell and their value in use. The excess of carrying value over the estimated recoverable amount is charged to the interim consolidated statement of income.

Accounts payable and accruals

Liabilities are recognised for amounts to be paid in the future for goods or services received, whether or not billed to the Group.

Provision

Provision is recognised when the Group has an obligation (legal or constructive) arising from a past event, and the costs to settle the obligation are both probable and can be measured reliably.

Zakat

Zakat is provided for the Company and its subsidiaries in accordance with Saudi Arabian fiscal regulations. The provision is charged to the interim consolidated statement of income. Additional amounts, if any, that become due on finalization of an assessment are accounted for in the period in which the assessment is finalized.

Employees' terminal benefits

Provision is made for amounts payable related to the accumulated periods of service at the interim consolidated balance sheet date in accordance with the employees' contracts of employment.

Revenue

Operating revenue

Operating revenue represents the invoiced value of services rendered by the Group to the patients and is recognized, net of discount, when services are performed.

Sales

Sales represent the invoiced value of medicines and drugs supplied by the Group and are recognized, net of discount, when the significant risks and rewards of ownership of those goods have passed to the buyer and the amount of revenue can be measured reliably; normally on delivery to the customer/patient.

Commission income on term deposits is recognised on an accrual basis.

Operating lease

Operating lease payments are recognised as an expense in the interim consolidated statement of income on a straight-line basis over the lease term.

Mouwasat Medical Services Company and its Subsidiaries

(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - continued

At 31 December 2015

3 SIGNIFICANT ACCOUNTING POLICIES - (continued)

Expenses

Selling and distribution expenses are those that specifically relate to marketing personnel, advertisements, promotions as well as allowance for doubtful debts. All other expenses other than amortization of intangible assets and financial charges are allocated on a consistent basis to direct costs and general and administration expenses in accordance with allocation factors determined as appropriate by the Group.

Foreign currencies

Transactions in foreign currencies are recorded in Saudi Riyals (SR) at the rate of exchange ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange ruling at the interim consolidated balance sheet date. All differences are taken to interim consolidated statement of income.

Borrowing cost

Borrowing costs that are directly attributable to the construction of an asset are capitalised up to stage when substantially all the activities necessary to prepare the qualifying asset for its intended use are completed and, thereafter, such costs are charged to the interim consolidated statement of income.

Earnings per share

Earnings per share from main operations is calculated by dividing income from main operations for the period/year by the weighted average of number of outstanding shares during the period/ year.

Earnings per share from net income is calculated by dividing the net income for the period/year by the weighted average number of outstanding shares during the period/year.

Segmental reporting

A segment is a distinguishable component of the Group that is engaged either in providing products or services (a business segment) or in providing products or services within a particular economic environment (a geographic segment), which is subject to risks and rewards that are different from those of other segments. Because the Group carries out its activities entirely in the Kingdom of Saudi Arabia, reporting is provided by business segment only.

Mouwasat Medical Services Company and its Subsidiaries
(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS - (continued)

At 31 December 2015

4 TERM DEPOSITS

Term deposits are placed with local banks with maturities of more than three months and earn commission income at an average rate of 1.05% to 1.1% (31 December 2014: 1%).

5 SHORT TERM LOANS

The short term loans were obtained from various local banks for the purpose of financing and construction of the new projects. These borrowings are secured by promissory note issued by the Company and carry commission charges at prevailing market borrowing rates.

6 SHARE CAPITAL

The authorised, issued and fully paid share capital of the Company is divided into 50 million shares (31 December 2014: 50 million shares) of SR 10 each.

7 DIVIDENDS

The board of directors at their meeting held on 7 Rabi'II 1436H (corresponding to 27 January 2015) proposed a cash dividend of SR 2.0 per share amounting to SR 100 million for the year ended 31 December 2014 which was subsequently approved by the shareholders in the General Assembly Meeting held on 12 Jumada'II 1436H (corresponding to 1 April 2015) (31 December 2014: the Board of Directors at their meeting held on 13 Safar 1435H (corresponding to 16 December 2013) proposed a cash dividend of SR 2.0 per share amounting to SR 100 million for the year ended 31 December 2013 which was subsequently approved by the shareholders in the General Assembly Meeting held on 2 Jamadah'II 1435H (corresponding to 2 April 2014)).

8 EARNINGS PER SHARE

Earnings per share from main operations is calculated by dividing income from main operations for the period/ year by the weighted average of number of outstanding shares during the period/ year.

Earnings per share from net income is calculated by dividing the net income for the period/ year by the weighted average number of outstanding shares during the period/ year.

Mouwasat Medical Services Company and its Subsidiaries
(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS - (continued)
 At 31 December 2015

9 SEGMENTAL INFORMATION

Business segments:

Consistent with the Group's internal reporting process, business segments have been approved by management in respect of the Group's activities. Transactions between the business segments are reported at cost. The Group's revenue, gross profit, property and equipment, total assets and total liabilities, by business segment, are as follows:

	<i>In-patient</i> <i>SR</i>	<i>Out-patient</i> <i>SR</i>	<i>Pharmaceuticals</i> <i>SR</i>	<i>Total</i> <i>SR</i>
<i>For the three months period ended 31 December 2015 (Unaudited)</i>				
Revenue	101,253,748	128,244,598	46,356,293	275,854,639
Gross profit	50,705,223	64,222,596	14,716,577	129,644,396
<i>For the year ended 31 December 2015 (Unaudited)</i>				
Revenue	378,315,919	486,504,250	189,963,922	1,054,784,091
Gross profit	195,962,759	251,929,320	53,628,701	501,520,780
<i>As at 31 December 2015 (Unaudited)</i>				
Property and equipment	569,739,653	448,518,450	193,953,925	1,212,212,028
Total assets	881,365,558	693,840,971	300,019,339	1,875,225,868
Total liabilities	307,942,371	247,692,777	113,803,836	669,438,984
<i>For the three months period ended 31 December 2014 (Unaudited)</i>				
Revenue	89,078,960	109,620,831	48,477,523	247,177,314
Gross profit	47,037,228	55,261,361	15,187,977	117,486,566
<i>For the year ended 31 December 2014 (Audited)</i>				
Revenue	333,536,131	433,929,083	185,231,162	952,696,376
Gross profit	178,810,238	232,634,036	54,640,175	466,084,449
<i>As at 31 December 2014 (Audited)</i>				
Property and equipment	508,773,260	400,523,630	173,199,407	1,082,496,297
Total assets	782,256,386	629,206,224	289,094,751	1,700,557,361
Total liabilities	281,974,760	226,805,785	104,208,063	612,988,608

Geographical segments:

All of the Group's operating assets and principal markets of activity are located in the Kingdom of Saudi Arabia.

10 COMPARATIVE FIGURES

Certain of the prior year/ period amounts have been reclassified to conform with the presentation in the current year/ period .